BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Biofil Chemicals & Pharmaceuticals Ltd has announced the closure of its trading window for the quarter ended June 30, 2026. This closure, effective July 1, 2026, is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will reopen 48 hours after the un-audited financial results for the quarter are declared to the stock exchanges. All designated persons, their immediate relatives, and connected persons are restricted from trading in the company's securities during this period. The date for the board meeting to consider these results will be announced later.

Biofil Chemicals & Pharmaceuticals Ltd. announced its audited financial results for the year ended March 31, 2026, following a Board of Directors meeting held on May 30, 2026. The results, along with the audit report, statement of assets and liabilities, and cash flow statement, were approved. The company will submit the results in XBRL mode and upload them on its website and stock exchange websites. A publication with a QR code linking to the complete financial results will be published in Hindi and English newspapers.

Biofil Chemicals & Pharmaceuticals Ltd's Board of Directors approved the audited financial results for the fourth quarter and financial year ended March 31, 2026, along with the audit report, statement of assets and liabilities, and cash flow statement. The board also declared an unmodified opinion of the auditors on the annual audited financial results. The results will be submitted in XBRL mode and uploaded on the company's website and stock exchange websites. Publication of key details with a QR code will be made in Hindi and English newspapers.

Biofil Chemicals & Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the fourth quarter and financial year ended March 31, 2026. The trading window will open 48 hours after the declaration of the results. The company has also submitted the information in XBRL mode.

Biofil Chemicals & Pharmaceuticals Ltd. is requesting holders of physical shares to update their PAN, KYC, nomination, and other details as per SEBI regulations. This is to ensure seamless communication, regulatory compliance, and proper credit of dividends. The company has sent draft intimation letters to shareholders for updating PAN, choice of nomination, contact details, bank account details, and specimen signature.

Biofil Chemicals & Pharmaceuticals Ltd informs about the SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, regarding 'Ease of Doing Investment – Special Window for Transfer and Dematerialisation of Physical Securities'. This circular allows a special window for transfer and dematerialisation of physical securities sold/purchased before April 01, 2019. The facility is available for one year from February 05, 2026, to February 04, 2027. This also includes transfer requests which were earlier submitted but were rejected, returned, or remained unattended due to deficiencies in documentation or procedural requirements. The securities so transferred will be mandatorily credited to the transferee only in demat mode and will be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred/lien marked/pledged during the said lock-in period. Shareholders are requested to furnish the required documents to the Company’s Registrar and Share Transfer Agents (‘RTA’), i.e. Ankit Consultancy Private Limited, for availing this opportunity.

Biofil Chemicals & Pharmaceuticals Ltd has announced the closure of the trading window for all designated persons, their immediate relatives, and connected persons. The closure is effective from April 01, 2026, and is in accordance with the Company's Code of Conduct and SEBI regulations. The trading window will reopen 48 hours after the audited financial results for the quarter and financial year ended March 31, 2026, are generally available. Directors, KMP’s, Designated Employees, Connected Persons, Fiduciaries, and their immediate relatives are advised not to deal in the securities of the Company during the closure period. The date of the Board Meeting for the purpose of consideration of Audited Financial Results for the Quarter and Financial Year ended March 31, 2026, will be intimated in due course.

Biofil Chemicals & Pharmaceuticals Ltd. has announced its un-audited financial results for the quarter and nine months ended on 31st December, 2025. The company's revenue from operations stands at INR 3,340.22 lakhs for the quarter and INR 2,505.12 lakhs for the nine months ended. The total income for the quarter is INR 1,360.42 lakhs and INR 2,511.97 lakhs for the nine months ended. The company's net profit before exceptional items and tax for the quarter is INR 10.67 lakhs and INR 11.17 lakhs for the nine months ended.

Biofil Chemicals & Pharmaceuticals Ltd. announced the financial results for the quarter and nine months ended on 31st December 2025. The un-audited standalone financial results were approved in a Board Meeting on 13th February 2026. The company's revenue from operations stands at 3,340.22 Lakhs for the quarter and 2,505.12 Lakhs for the nine months period.

Biofil Chemicals & Pharmaceuticals Ltd has clarified that there are no material developments in the company that would significantly impact the price of its equity shares. The company believes that the recent change in price and volume may be due to market conditions and the current scenario in the stock market. Biofil is committed to complying with SEBI (LODR) Regulations, 2015, and will disclose any required announcements or disclosures immediately.